NCI 8628: A randomized phase 2 study of ziv‐aflibercept and high‐dose interleukin 2 or high‐dose interleukin 2 alone for inoperable stage III or IV melanoma
Sign Up to like & getrecommendations! Published in 2018 at "Cancer"
DOI: 10.1002/cncr.31734
Abstract: Interleukin 2 (IL‐2) is a growth factor for T and natural killer cells, promotes proinflammatory cytokines, and can lead to durable responses in patients with melanoma. Vascular endothelial growth factor (VEGF) promotes angiogenesis and modulates… read more here.
Keywords: ziv aflibercept; high dose; dose interleukin; nci 8628 ... See more keywords
Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM
Sign Up to like & getrecommendations! Published in 2017 at "Clinical genitourinary cancer"
DOI: 10.1016/j.clgc.2016.10.008
Abstract: &NA; ProleukinR Observational Study to Evaluate the Treatment Patterns and Clinical Response in Malignancy (PROCLAIMSM) is the largest observational clinical database of high‐dose interleukin‐2 (HD IL‐2)‐treated patients in the US. Herein, the survival and outcome… read more here.
Keywords: cell carcinoma; renal cell; dose interleukin; high dose ... See more keywords
The numbers of peripheral regulatory T cells are reduced in patients with psoriatic arthritis and are restored by low-dose interleukin-2
Sign Up to like & getrecommendations! Published in 2020 at "Therapeutic Advances in Chronic Disease"
DOI: 10.1177/2040622320916014
Abstract: Background: Although regulatory T cells (Tregs) play crucial roles in the maintenance of immune hemostasis, the numbers of peripheral Tregs in patients with psoriatic arthritis (PsA) remain unclear. We measured these numbers and the efficacy… read more here.
Keywords: psoriatic arthritis; dose interleukin; low dose; numbers peripheral ... See more keywords
Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma
Sign Up to like & getrecommendations! Published in 2017 at "BMC Urology"
DOI: 10.1186/s12894-016-0192-0
Abstract: BackgroundImmunotherapy with high-dose interleukin-2 (HD-IL2) results in long-term survival in some metastatic renal cell carcinoma (mRCC) patients but has significant acute toxicities. Biomarkers predicting response to therapy are needed to better select patients most likely… read more here.
Keywords: renal cell; dose interleukin; response; high dose ... See more keywords
High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute
Sign Up to like & getrecommendations! Published in 2017 at "Journal for Immunotherapy of Cancer"
DOI: 10.1186/s40425-017-0279-5
Abstract: BackgroundDurable remissions are observed in a fraction of metastatic melanoma patients treated with high-dose interleukin-2 (HD IL-2). Early studies reported overall (OR) and complete response (CR) rates of 16% and 8% respectively. Toxicity limited use… read more here.
Keywords: high dose; dose interleukin; university pittsburgh;
High‐Dose Interleukin‐2: Evaluation of a standardized order set for biotherapy in an intensive care unit
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Journal of Oncology Nursing"
DOI: 10.1188/17.cjon.e49-e53
Abstract: BACKGROUND: Life‐threatening toxicity may result from administration of high‐dose (HD) interleukin‐2 (IL‐2). Patients receiving HD IL‐2 treatment often experience severe adverse side effects, which result in the interruption of treatment. OBJECTIVES: A standardized order set… read more here.
Keywords: dose interleukin; standardized order; high dose; order set ... See more keywords
Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results of a Proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2021.778459
Abstract: High-dose interleukin-2 (HD IL-2) has curative potential in metastatic melanoma (MM) and renal cell carcinoma (RCC). Radiotherapy (RT) kills cancer cells and induces immunomodulatory effects. Prospective trials exploring clinical and immunological properties of combined RT/HD… read more here.
Keywords: dose interleukin; high dose; treatment; metastatic melanoma ... See more keywords
Low Dose Interleukin-2 Ameliorates Sjögren’s Syndrome in a Murine Model
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Medicine"
DOI: 10.3389/fmed.2022.887354
Abstract: Sjögren’s syndrome (SS) is a systemic autoimmune disease with no efficient treatment, and it is associated with dysregulated immune cells and impaired interleukin (IL)-2 signaling. IL-2 is critical for the development and maintenance of Treg… read more here.
Keywords: dose interleukin; gren syndrome; syndrome murine; ameliorates gren ... See more keywords
Acute and Chronic Cardiopulmonary Effects of High Dose Interleukin-2 Therapy: An Observational Magnetic Resonance Imaging Study
Sign Up to like & getrecommendations! Published in 2022 at "Diagnostics"
DOI: 10.3390/diagnostics12061352
Abstract: High dose interleukin-2 (IL-2) is known to be associated with cardiopulmonary toxicity. The goal of this study was to evaluate the effects of high dose IL-2 therapy on cardiopulmonary structure and function. Combined cardiopulmonary magnetic… read more here.
Keywords: effects high; dose interleukin; magnetic resonance; resonance imaging ... See more keywords